KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Enterprise Value (2016 - 2025)

Regeneron Pharmaceuticals has reported Enterprise Value over the past 17 years, most recently at -$8.6 billion for Q4 2025.

  • Quarterly results put Enterprise Value at -$8.6 billion for Q4 2025, up 4.52% from a year ago — trailing twelve months through Dec 2025 was -$8.6 billion (up 4.52% YoY), and the annual figure for FY2025 was -$8.6 billion, up 4.52%.
  • Enterprise Value for Q4 2025 was -$8.6 billion at Regeneron Pharmaceuticals, down from -$8.4 billion in the prior quarter.
  • Over the last five years, Enterprise Value for REGN hit a ceiling of -$3.5 billion in Q1 2021 and a floor of -$10.8 billion in Q4 2023.
  • Median Enterprise Value over the past 5 years was -$8.4 billion (2025), compared with a mean of -$7.9 billion.
  • Biggest five-year swings in Enterprise Value: tumbled 101.23% in 2022 and later grew 23.85% in 2025.
  • Regeneron Pharmaceuticals' Enterprise Value stood at -$5.7 billion in 2021, then tumbled by 35.96% to -$7.7 billion in 2022, then tumbled by 40.07% to -$10.8 billion in 2023, then increased by 16.9% to -$9.0 billion in 2024, then grew by 4.52% to -$8.6 billion in 2025.
  • The last three reported values for Enterprise Value were -$8.6 billion (Q4 2025), -$8.4 billion (Q3 2025), and -$7.5 billion (Q2 2025) per Business Quant data.